The EMA has extended the indications for Darzalex (daratumumab) to the treatment of adults at high risk of developing ...

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

Multiple myeloma (MM) is a form of blood cancer that originates from plasma cells – part of the white blood cell produced by ...

DataM Intelligence | competitive Intelligence Explore the evolving Multiple Myeloma market: drug innovations, emerging therapies, and key p ...

A Harrisburg grandfather bikes thousands of miles a yearfighting against his multiple myeloma cancer. CBS 21’s Alex Thill sat ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

Despite outward appearances, people with SMM still experience some of the physical changes associated with multiple myeloma. These may include: A large number of plasma cells in bone marrow A high ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

England is set to become the first health system globally to offer the "Trojan horse" therapy, belantamab mafodotin (Blenrep), developed by GSK, for patients with multiple myeloma, following its ...

Seoul St. Mary's Hospital, which established the first blood hospital in Korea, revealed the results of the treatment of ...